Intervention Review

Anti-angiogenic therapies for metastatic colorectal cancer

  1. Anna Dorothea ADW Wagner1,*,
  2. Dirk Arnold2,
  3. Axel AG Grothey3,
  4. Johannes Haerting4,
  5. Susanne Unverzagt5

Editorial Group: Cochrane Colorectal Cancer Group

Published Online: 8 JUL 2009

Assessed as up-to-date: 12 MAY 2009

DOI: 10.1002/14651858.CD005392.pub3


How to Cite

Wagner ADADW, Arnold D, Grothey AAG, Haerting J, Unverzagt S. Anti-angiogenic therapies for metastatic colorectal cancer. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD005392. DOI: 10.1002/14651858.CD005392.pub3.

Author Information

  1. 1

    Centre Hospitalier Universitaire Vaudois, Fondation du Centre Pluridisciplinaire d'Oncologie, Lausanne, Switzerland

  2. 2

    Martin Luther University Halle Wittenberg, Department of Medicine IV, Halle/Saale, Sachsen Anhalt, Germany

  3. 3

    Mayo Clinic College of Medicine, Division of Medical Oncology, Rochester, USA

  4. 4

    Martin Luther University Halle Wittenberg, Institute of Medical Epidemiology, Biostatistics and Informatics, Halle (Saale), Sachsen Anhalt, Germany

  5. 5

    Martin Luther University Halle-Wittenberg, Institute of Medical Epidemiology, Biostatistics and Informatics, Halle (Saale), Germany

*Anna Dorothea ADW Wagner, Fondation du Centre Pluridisciplinaire d'Oncologie, Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 46, Lausanne, 1011, Switzerland. Anna-Dorothea.Wagner@gmx.de.

Publication History

  1. Publication Status: New
  2. Published Online: 8 JUL 2009

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Stephen Clarke, Matt Burge, Cassandra Cordwell, Peter Gibbs, William Reece, Niall Tebbutt, An Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT], BMC Cancer, 2013, 13, 1, 120

    CrossRef

  2. 2
    L. Lacaze, M. Scotté, Diaphragmatic rupture, a new complication of Bevacizumab, European Journal of Surgical Oncology (EJSO), 2012, 38, 11, 1079

    CrossRef

  3. 3
    Juan Andrés Rubiano, Alejandro Garrido, Juan Sebastián Castillo, Uso de bevacizumab en pacientes con cáncer de colon metastásico en el Instituto Nacional de Cancerología: una serie de casos, Revista Colombiana de Cancerología, 2012, 16, 4, 227

    CrossRef

  4. 4
    Meredith L. Rees, Aarif Y. Khakoo, Molecular Mechanisms of Hypertension and Heart Failure Due to Antiangiogenic Cancer Therapies, Heart Failure Clinics, 2011, 7, 3, 299

    CrossRef

  5. 5
    Daniel Staub, Arend F.L. Schinkel, Blai Coll, Stefano Coli, Antonius F.W. van der Steen, Jess D. Reed, Christian Krueger, Kai E. Thomenius, Dan Adam, Eric J. Sijbrands, Folkert J. ten Cate, Steven B. Feinstein, Contrast-Enhanced Ultrasound Imaging of the Vasa Vasorum, JACC: Cardiovascular Imaging, 2010, 3, 7, 761

    CrossRef

  6. 6
    Cheng E. Chee, Frank A. Sinicrope, Targeted Therapeutic Agents for Colorectal Cancer, Gastroenterology Clinics of North America, 2010, 39, 3, 601

    CrossRef

  7. 7
    Debashish Bose, Funda Meric-Bernstam, Wayne Hofstetter, David A Reardon, Keith T Flaherty, Lee M Ellis, Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care, The Lancet Oncology, 2010, 11, 4, 373

    CrossRef

  8. 8
    Anna Dorothea Wagner, Christoph Thomssen, Johannes Haerting, Susanne Unverzagt, Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer, The Cochrane Library,